KLRC1 and plasma cell myeloma: Furthermore, NKG2A blockade potentiated the activity of cytokine-activated, myeloma patient-derived NK cells against myeloma cell lines, demonstrating that anti-NKG2A mAbs can stimulate NK cells derived from cancer patients [61].